CR11554A - Pirrolo-Pirimidinas y Pirrolo-Piridinas - Google Patents

Pirrolo-Pirimidinas y Pirrolo-Piridinas

Info

Publication number
CR11554A
CR11554A CR11554A CR11554A CR11554A CR 11554 A CR11554 A CR 11554A CR 11554 A CR11554 A CR 11554A CR 11554 A CR11554 A CR 11554A CR 11554 A CR11554 A CR 11554A
Authority
CR
Costa Rica
Prior art keywords
pirrolo
compounds
pirimidinas
piridinas
alk
Prior art date
Application number
CR11554A
Other languages
English (en)
Inventor
Catherine Leblanc
Robert Alexander Pulz
Nikolaus Johannes Stiefl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR11554A publication Critical patent/CR11554A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos de la formula I, en forma libre o de sal o de solvato, en donde X, T1, T3 y T4 tienen los significados indicados en la memoria descriptiva, son utiles para el tratamiento de las enfermedades mediadas por el receptor de ALK-5 y/o ALK-4. Tambien se describen composiciones farmaceuticas que contienen los compuestos, y procesos para la preparacion de los compuestos.
CR11554A 2008-01-11 2010-07-02 Pirrolo-Pirimidinas y Pirrolo-Piridinas CR11554A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08150182 2008-01-11

Publications (1)

Publication Number Publication Date
CR11554A true CR11554A (es) 2010-08-11

Family

ID=39445770

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11554A CR11554A (es) 2008-01-11 2010-07-02 Pirrolo-Pirimidinas y Pirrolo-Piridinas

Country Status (22)

Country Link
US (1) US8314112B2 (es)
EP (1) EP2242756A2 (es)
JP (1) JP5643110B2 (es)
KR (1) KR20100116606A (es)
CN (1) CN101970435B (es)
AR (1) AR070127A1 (es)
AU (1) AU2009203694B2 (es)
BR (1) BRPI0907231A2 (es)
CA (1) CA2711845A1 (es)
CL (1) CL2009000028A1 (es)
CO (1) CO6331340A2 (es)
CR (1) CR11554A (es)
EA (1) EA201001126A1 (es)
EC (1) ECSP10010335A (es)
IL (1) IL206819A0 (es)
MA (1) MA31952B1 (es)
MX (1) MX2010007605A (es)
PE (1) PE20091306A1 (es)
TN (1) TN2010000305A1 (es)
TW (1) TW200934781A (es)
WO (1) WO2009087225A2 (es)
ZA (1) ZA201004602B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007003444A1 (es) * 2006-11-30 2008-06-27 Genentech Inc Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
WO2009085185A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
WO2009126584A1 (en) 2008-04-07 2009-10-15 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
EP2300013B1 (en) 2008-05-21 2017-09-06 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
CA2676946A1 (en) * 2009-08-28 2011-02-28 Lucie Peduto Adam12 inhibitors and their use against inflammation-induced fibrosis
EP2475666A2 (en) 2009-09-11 2012-07-18 Trius Therapeutics, Inc. Gyrase inhibitors
ES2667049T3 (es) * 2010-02-05 2018-05-09 Merck Patent Gmbh Derivados de heteroaril-[1,8]naftiridina
EA022064B1 (ru) 2010-02-22 2015-10-30 Мерк Патент Гмбх Гетариламинонафтиридины в качестве ингибиторов атф-связывающих белков
EP2539338A1 (en) * 2010-02-24 2013-01-02 Syngenta Participations AG Novel microbicides
JP5744021B2 (ja) 2010-06-30 2015-07-01 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
ME02663B (me) 2010-10-06 2017-06-20 Glaxosmithkline Llc Derivati benzimidazola kao inhibitori pi3 kinaze
EP2688887B1 (en) 2011-03-23 2015-05-13 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
JP5999177B2 (ja) 2011-05-04 2016-09-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
KR20140040770A (ko) 2011-07-01 2014-04-03 노파르티스 아게 암 치료에 사용하기 위한 cdk4/6 억제제 및 pi3k 억제제를 포함하는 조합 요법
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
CN104350056A (zh) 2012-06-07 2015-02-11 霍夫曼-拉罗奇有限公司 端锚聚合酶的吡咯并嘧啶酮和吡咯并吡啶酮抑制剂
WO2014006554A1 (en) * 2012-07-03 2014-01-09 Aurigene Discovery Technologies Limited 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
EP2970311A4 (en) 2013-03-14 2016-11-23 Brigham & Womens Hospital BMP INHIBITORS AND METHODS OF USE
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9776997B2 (en) 2013-06-04 2017-10-03 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-A]pyridines and their use
CA2939793A1 (en) 2014-02-19 2015-08-27 Bayer Pharma Aktiengesellschaft 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines
JP2017514793A (ja) * 2014-03-26 2017-06-08 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害用組成物及びｂｍｐ阻害方法
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
WO2016011019A1 (en) 2014-07-15 2016-01-21 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp
EP3197884B1 (en) 2014-09-26 2019-03-06 Gilead Sciences, Inc. Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
CA2969268A1 (en) 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Heteroaryl-substituted imidazo[1,2-a]pyridines and their use
US10526287B2 (en) 2015-04-23 2020-01-07 Constellation Pharmaceuticals, Inc. LSD1 inhibitors and uses thereof
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
US9708333B2 (en) 2015-08-12 2017-07-18 Incyte Corporation Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
FR3041640B1 (fr) 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
PE20181073A1 (es) 2015-12-17 2018-07-04 Gilead Sciences Inc Compuestos inhibidores de la quinasa de union a tank
CA3008171A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
TWI753892B (zh) 2016-03-28 2022-02-01 美商英塞特公司 作為ｔａｍ抑制劑之吡咯并三嗪化合物
DK3442977T3 (da) 2016-04-15 2023-10-09 Blueprint Medicines Corp Inhibitorer af activinreceptorlignende kinase
TWI753037B (zh) 2016-10-26 2022-01-21 美商星座製藥公司 Lsd1抑制劑及其用途
EP4331679A3 (en) 2017-06-21 2024-04-03 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN109384782A (zh) * 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
MX2020003375A (es) 2017-09-27 2020-08-03 Incyte Corp Sales de inhibidores de macrofagos asociados a tumores (tam).
WO2019079649A1 (en) * 2017-10-18 2019-04-25 Blueprint Medicines Corporation SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-RELATED KINASE
MX2020006613A (es) 2017-12-22 2020-11-13 Ravenna Pharmaceuticals Inc Derivados de aril-bipiridina amina como inhibidores de fosfatidilinositol fosfato cinasa.
CN111867632B (zh) * 2018-03-23 2024-08-16 赛途公司 骨骼肌肥大诱导剂的alk5抑制剂
TWI832871B (zh) 2018-06-29 2024-02-21 美商英塞特公司 Axl/mer 抑制劑之調配物
WO2020012357A1 (en) * 2018-07-10 2020-01-16 Integral Biosciences Pvt. Ltd. Heterocyclic compounds and methods of use
CN111018858B (zh) * 2018-10-10 2022-11-18 复旦大学 杂环类衍生物及其制备方法和用途
TW202415643A (zh) * 2018-12-12 2024-04-16 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
KR20200105246A (ko) * 2019-02-28 2020-09-07 한미약품 주식회사 아데노신 수용체 길항제로서 신규 화합물 및 이를 포함하는 약학 조성물
CN118373808A (zh) * 2020-03-16 2024-07-23 上海海雁医药科技有限公司 取代的嘧啶或吡啶胺衍生物、其组合物及医药上的用途
CN113698395B (zh) * 2020-05-22 2023-12-08 赛诺哈勃药业（成都）有限公司 转化生长因子受体拮抗剂、其制备方法和应用
MX2022015410A (es) 2020-06-05 2023-03-13 Kinnate Biopharma Inc Inhibidores de las cinasas receptoras del factor de crecimiento de fibroblastos.
CA3184990A1 (en) 2020-07-15 2022-01-20 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors
US20240116947A1 (en) 2020-07-15 2024-04-11 Chiesi Farmaceutici S.P.A. Pyrido oxazine derivatives as alk5 inhibitors
US20240190891A1 (en) 2020-07-15 2024-06-13 Chiesi Farmaceutici S.P.A. Pyrido oxazine amino derivatives as alk5 inhibitors
US20240116948A1 (en) 2020-12-23 2024-04-11 Chiesi Farmaceutici S.P.A. Pyrido oxazine derivatives as alk5 inhibitors
CN118201915A (zh) 2021-09-21 2024-06-14 奇斯药制品公司 作为alk5抑制剂的哒嗪基氨基衍生物
WO2023208986A1 (en) 2022-04-27 2023-11-02 Chiesi Farmaceutici S.P.A. Imidazole derivatives as alk5 inhibitors
CN118126036A (zh) * 2022-12-01 2024-06-04 复旦大学 7-氮杂吲哚类化合物及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL175347B1 (pl) 1992-04-03 1998-12-31 Upjohn Co Trójpierścieniowe heterocykliczne aminy aktywne farmaceutycznie
US6686366B1 (en) * 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
ATE245156T1 (de) * 1999-03-11 2003-08-15 Neurogen Corp Aryl-annellierte disubstituierte pyridine : nk3 rezeptor-liganden
DK1246623T3 (da) 1999-12-02 2006-11-13 Osi Pharm Inc Forbindelser, som er specifikke for adenosin A1-, A2a- og A3-receptor og anvendelser deraf
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
JP4579497B2 (ja) 2000-12-01 2010-11-10 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アデノシンａ１、ａ２ａ、およびａ３受容体に特異的な化合物、ならびにそれらの使用
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
GB0100622D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
EP1450811B1 (en) 2001-11-30 2009-10-21 OSI Pharmaceuticals, Inc. Compounds specific to adenosine A1 and A3 receptors and uses thereof
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
ATE398125T1 (de) * 2003-03-12 2008-07-15 Millennium Pharm Inc Chinazolin-derivate als tgf-beta-inhibitoren
US20050205625A1 (en) * 2004-03-16 2005-09-22 House Arthur G Container support device, system, and method
DE602006013792D1 (de) 2005-02-18 2010-06-02 Solvay Pharm Gmbh Pharmazeutische zusammensetzungen mit nep-inhibitoren, inhibitoren des endogenes endothelin produzierenden systems und diuretika
US20060205625A1 (en) 2005-02-18 2006-09-14 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
US20070014956A1 (en) * 2005-07-14 2007-01-18 Mccarthy Dillon P Adhesive tape device
DK1962830T3 (da) * 2005-12-23 2013-06-24 Glaxosmithkline Llc Azaindolhæmmere af aurorakinaser.

Also Published As

Publication number Publication date
EA201001126A1 (ru) 2011-02-28
US20090181941A1 (en) 2009-07-16
WO2009087225A2 (en) 2009-07-16
CA2711845A1 (en) 2009-07-16
JP2011509279A (ja) 2011-03-24
AR070127A1 (es) 2010-03-17
CO6331340A2 (es) 2011-10-20
ECSP10010335A (es) 2010-08-31
WO2009087225A3 (en) 2009-11-05
JP5643110B2 (ja) 2014-12-17
MA31952B1 (fr) 2010-12-01
BRPI0907231A2 (pt) 2019-09-24
CN101970435A (zh) 2011-02-09
AU2009203694B2 (en) 2012-04-26
EP2242756A2 (en) 2010-10-27
PE20091306A1 (es) 2009-09-24
KR20100116606A (ko) 2010-11-01
TN2010000305A1 (en) 2011-11-11
TW200934781A (en) 2009-08-16
AU2009203694A1 (en) 2009-07-16
US8314112B2 (en) 2012-11-20
IL206819A0 (en) 2010-12-30
MX2010007605A (es) 2010-08-02
CN101970435B (zh) 2014-07-02
ZA201004602B (en) 2011-03-30
CL2009000028A1 (es) 2009-07-17

Similar Documents

Publication Publication Date Title
CO6331340A2 (es) Pirrolo-pirimidinas y pirrolo piridinas
SV2010003463A (es) Compuestos organicos
UY28955A1 (es) Nuevos derivados fluoroglicosídicos de pirazoles, medicamentos que contienen estos compuestos, y el empleo de los mismos
CU20120013A7 (es) Derivados de oxacina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
CO7400867A2 (es) Modificador del sabor dulce
EA201001687A1 (ru) Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 )
CU20100062A7 (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
ECSP056134A (es) Derivados de quinuclidina que se enlazan con los receptores muscarínicos m3
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
GT200500281A (es) Compuestos organicos.
CO6620050A2 (es) Derivados de aminopirimidina como moduladores de la lrrk2
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
UY30282A1 (es) Compuestos quimicos
EA201000615A1 (ru) Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы)
CR20120332A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos.
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
DOP2006000087A (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos
DOP2010000317A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
SV2011003839A (es) Agentes antifungicos
UY32016A (es) Compuesto de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno
CU20100147A7 (es) Pirrolo-pirimidinas y pirrolo-piridinas
UY30849A1 (es) S-nitrosotioles estables, procedimeinto de sintesis y uso
CL2008003090A1 (es) Forma cristalina 1 del etanoato de n-{4-(3-amino-1h-indazol-4-il)fenil}-n'-(2-fluoro-5-metilfenil)urea*1/4; procedimiento de preparacion; composicion farmaceutica que la comprende; utiles en el tratamiento del cancer.
CU20100011A7 (es) Compuestos orgánicos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)